NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for a fee; Altria in turn will evaluate the formulations. The new agreements will continue through March 31, 2023. Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. In addition, the technology has shown the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times as well as decrease time of onset significantly.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer